2.1 Establishing a reasonable price for an orphan drug (2020) Drug development for very rare conditions will always have terrible QALYs/$. What should be the “correction term” that would justify it? How costly-for-the-Republic would be too costly? https:
260 followers
2,648 followers
@shaklakhani https://t.co/6CaNz3cUNW Lots of trial & error but can’t go wrong (to start) by estimating effect size/impact on QoL followed by R&D/COGS. Connect w/payors and patient advocacy organizations and, (depending on how rare the indication)
2,672 followers
How to price orphan drugs? How to get sustainable prices for the third-payer and adequate return of investments for the manufacturers? A new, general method proposed by Berdud, Drummond and Towse. #orphandrugs https://t.co/v1qRt5Qpty https://t.co/sMbatRCq
42 followers
RT @OHENews: New article published in cost-effectiveness and resource allocation by Berdud, Drummond and Towse (2020) proposes a ‘reasonabl…